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Abstract
Background: During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) has been identified as
a key regulator of serum LDL-cholesterol (LDL-C) levels. PCSK9 is secreted by the liver into the plasma and binds
the hepatic LDL receptor, causing its subsequent degradation. In humans, gain-of-function mutations in PCSK9
cause a form of familial hypercholesterolemia that manifests with dramatically increased serum levels of LDL-C,
while loss-of-function mutations in PCSK9 are associated with significantly decreased LDL-C and cardiovascular risk.
Results: Initial studies in animals and cultured cells demonstrated that statins increased PCSK9 mRNA expression,
resulting in many research groups exploring the effect of statins on PCSK9 levels in humans. We first reported that
statins increased human PCSK9 circulating protein levels. Additional researchers subsequently confirmed these
observations, further prompting many laboratories including our own to examine the effect of other lipid lowering
medications on PCSK9 levels. Our observation that fenofibrate (200 mg/day) significantly increased PCSK9 levels
was confirmed by another laboratory, and an additional group demonstrated that ezetimibe also increased PCSK9
levels.
Conclusions: It has become clear that the major classes of commonly prescribed lipid-lowering medications
increase serum PCSK9 levels. These observations almost certainly explain why these agents are not more effective
in lowering LDL-C and suggest that efforts should be made toward the development of new LDL-C lowering
medications that either do not increase circulating PCSK9 levels or work through decreasing or inhibiting PCSK9.
Discovery of PCSK9, mechanism of action, and
genetic findings
The discovery of proprotein convertase subtilisin kexin
type 9 (PCSK9) and the subsequent observations that
genetic mutations in PCSK9 can drastically affect low
density lipoprotein cholesterol (LDL-C) levels and the
risk for cardiovascular disease ushered in a new era of
understanding about the regulation of circulating LDL-
C [1-6]. PCSK9 was first described by Seidah and
co-workers in 2003 as a protein important in liver
regeneration and neuronal differentiation [7]. These
researchers originally named the protein (which was the
ninth described member of thep r o p r o t e i ns u b t i l i s i n
kexin family of proteins) neuronal apoptosis regulated
convertase-1 (NARC-1).
Later that year, Abifadel and colleagues reported the
discovery of 2 mutations in PCSK9 that resulted in
familial hypercholesterolemia (FH), a genetic disease
characterized by greatly increased levels of LDL-C and
early onset of atherosclerosis and cardiovascular events
[8]. Prior to that report, FH had been associated with
mutations in either the low density lipoprotein receptor
(LDLR) or apolipoprotein B (ApoB). Mutations in these
2 genes however, could not account for all cases of FH,
and the observation that PCSK9 mutations could result
in FH established PCSK9 as third important locus of
FH [8].
In 2004, Maxwell and colleagues reported that overex-
pression of PCSK9 in mice resulted in a phenotype that
was very similar to that of an LDLR knockout model,
with large increases in circulating non high density lipo-
protein cholesterol (HDL-C), and a virtual absence of
measureable LDLR protein [9]. In addition, these
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tle effect on LDLR mRNA levels suggesting that PCSK9
was acting at the protein level through degradation of
the hepatic LDLR [9]. These interesting observations
were followed by a number of reports over the next few
years further elucidating the mechanism by which
PCSK9 decreases LDLR levels. It was gradually recog-
nized that PCSK9 was a protease secreted by the liver
into the plasma, which was then able to bind to and
cause the degradation of hepatic LDLR [10-19]. The
mechanism by which PCSK9 degrades LDLR has turned
out to be more complex than originally anticipated. As
Figure 1 shows, PCSK9 protein contains a pro-domain
that is self-cleaved during secretion and remains tightly
associated with the protein, as well as catalytic and
C-terminal domains. Recent studies suggest that after
self-cleavage and secretion, PCSK9 does not have to be
further enzymatically active to cause degradation of the
LDLR [20-22]. Instead, PCSK9 has been shown to bind
to the LDLR and subsequently target it for lysosomal
destruction within the hepatocyte [20-22]. This concept
of how PCSK9 acts to decrease hepatic LDLR levels has
been further supported by findings that disruption of
the binding of PCSK9 to the LDLR using anti-PCSK9
antibody results in preserved LDLR and decreased
LDL-C [23-26].
A tt h es a m et i m et h a tt h eb i o l o g yo fP C S K 9w a s
being increasingly understood, additional different acti-
vating PCSK9 mutations causing FH were being
reported in humans. It was increasingly recognized
that these patients were presenting with gain-of-func-
tion mutations of PCSK9, causing LDLR protein levels
to be markedly decreased with resulting FH and
accompanying increased cardiovascular risk [27-29].
Interest in PCSK9 then dramatically accelerated in
2006 with the report by Hobbs and co-workers that
approximately 3% of African-Americans were
heterozygous for loss-of-function mutations in PCSK9,
including mutations such as Y142X and C679X which
prevent the self-cleavage and secretion of the protein,
and that these subjects had significantly decreased
levels of serum LDL-C and approximately 80-90%
reduced cardiovascular risk [30]. Later that same year,
Hobbs and co-workers described a compound hetero-
zygote for PCSK9 loss-of-function mutations [31].
Remarkably, the subject who was a healthy 32 year-old
female, had a serum LDL-C level of 14 mg/dl [31].
More recently, a second subject, a 49 year-old male,
heterozygous for 2 monoallelic dominant negative
PCSK9 mutations has also been described and had a
LDL-C of 16 mg/dl [32].
Shortly after the loss-of-function findings in African-
Americans were described, it was also reported that 3%
of Caucasian subjects, while not possessing the com-
plete loss of function mutations observed in African-
Americans, did harbor mutations in PCSK9 that
resulted in decreased serum cholesterol levels [33].
Among these mutations, one of the most prominent
was R46L, which conferred a 10-20% reduction in circu-
lating LDL-C and a 50% reduced risk of cardiovascular
disease [33]. It was not intuitively obvious why the
R46L mutation should do this. Only when the labora-
tories of Humphries and co-workers and of Hobbs and
co-workers reported that the R46L mutation resulted in
significantly decreased levels of circulating PCSK9 did it
become apparent that the mutation was somehow low-
ering the amount of PCSK9 protein in the serum, and
that this reduction in serum PCSK9 was likely responsi-
ble for the beneficial effects on LDL-C and cardiovascu-
lar risk [34,35].
In light of all of the findings in humans showing that
PCSK9 mutations that decrease PCSK9 levels result in
decreased serum LDL-C and cardiovascular risk, there
has been tremendous increased interest in understand-
ing the normal role of PCSK9. In 2006, Costet and col-
leagues reported that PCSK9 mRNA expression was
decreased 73% in mice after fasting for a 24-hour period
and that PCSK9 mRNA expression levels returned to
normal following re-feeding with carbohydrate [36]. In
the same study, it was also shown that insulin increased
PCSK9 mRNA expression levels, suggesting that PCSK9
expression may be regulated by nutritional status via cir-
culating insulin levels [36].
Recently, Horton and colleagues examined the rela-
tionship between lathosterol, a marker of hepatic choles-
terol biosynthesis and circulating PCSK9 levels in
humans [37]. This group observed that lathosterol and
PCSK9 levels were highly correlated with each other
and declined together during the fasting state. Around
the same time, Rudling and colleagues conducted exten-
sive studies on the effect of prolonged fasting as well as
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Figure 1 PCSK9 protein structure and selected mutations.
PCSK9 protein includes a pro-domain (Pro) that is self-cleaved
during secretion and remains tightly associated, a catalytic domain,
and a C-terminal domain. Activating mutations such as D374Y cause
increased affinity for LDLR. Inactivating mutations such as Y142X
and C679X block self-cleavage and secretion of the protein. The
R46L mutation results in decreased circulating levels of PCSK9
protein, although the mechanism is not completely understood.
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tyramine on circulating PCSK9 and lathosterol and
observed that PCSK9 levels and lathosterol levels move
in virtual lockstep with each other and are both drama-
tically decreased by fasting, whereas LDL cholesterol
was little changed [38]. Together, these results would
seem to indicate that PCSK9 may represent a mechan-
i s mt h a th a se v o l v e df o rf i n e - t u n i n gp l a s m aL D L - C
levels, although this idea will have to be further probed.
In any event, all of the findings described above cer-
tainly established PCSK9 as a major player in the regula-
tion of LDL-C levels.
Statins, PCSK9, and the rule of 6%
Statins represent the most commonly prescribed class of
LDL-C lowering medications. Statins work through inhi-
biting the enzyme 3-Hydroxy-3-methyl-glutaryl-CoA
reductase (HMG-CoA reductase) which represents the
rate limiting step in cholesterol biosynthesis [39]. By
decreasing hepatic intracellular levels of cholesterol, sta-
tins increase the activity/nuclear translocation of the
transcription factor sterol regulatory element-binding
protein-2 (SREBP-2), which activates the LDLR gene
[40]. Increased expression of LDLR on the surface of
hepatocytes results in increased LDL binding and cata-
bolism which in turn decreases circulating LDL-C levels
by 30-40% or even more [40].
In 2003, Maxwell and co-workers first identified
PCSK9 as a novel target gene of SREBP and demon-
strated that hepatic PCSK9 mRNA levels were signifi-
cantly increased in SREBP-1a and SREBP-2 transgenic
mice [41]. In 2004, Dubuc and colleagues reported in a
study using HEPG2 cells and primary hepatocytes that
statins upregulate the expression of PCSK9 mRNA [42].
The induction of PCSK9 mRNA was described as being
highly dose dependent and was reversed by mevalonate
[42]. The authors also observed that human, mouse, and
rat PCSK9 promoters contain 2 typical conserved motifs
for cholesterol regulation, a sterol regulatory element
(SRE) and a Sp1 site. They concluded that PCSK9 regu-
lation is typical of that of the genes implicated in lipo-
protein metabolism (such as LDLR) and that PCSK9
was likely a target of SREBP-2 [42]. The following year,
Horton and co-workers demonstrated that PCSK9
knockout mice exhibited an exaggerated response to sta-
tin administration as demonstrated by increases in hepa-
tic LDLR and increased LDL-C clearance from their
plasma [43]. Together with additional results generated
in other laboratories [44-46], these data further sup-
ported the notion that statins increase the activity/
nuclear translocation of SREBP-2, a transcription factor
that activates both the LDLR and PCSK9 genes [41-46].
These data gave the first indication in vivo that a
P C S K 9i n h i b i t o rm i g h tb ea b l et or e d u c ep l a s m a
cholesterol beyond what was achievable with statins
alone [41-46].
These observations led a number of laboratories,
including our own, to examine the effects of statins on
human PCSK9 levels. In order to do this, there were 2
requirements. The first was a reliable immunoassay for
measuring human serum PCSK9 levels. The second was
a set of samples to test from patients who had blood
drawn at various time points prior to and after the
initiation of statin therapy. With regard to the develop-
ment of a reliable immunoassay, our group had begun
working on this goal in early 2006, and by 2007 had
established a robust, dual-monoclonal sandwich enzyme
linked immunosorbent assay (ELISA) that we were able
to use to show that human serum PCSK9 levels were
highly correlated with LDL-C levels [47]. Later that
same year, we were able to obtain a set of baseline and
endpoint samples from patients treated with placebo,
10 mg/day atorvastatin, or 40 mg/day atorvastatin for
12 weeks. Using our sandwich ELISA, we were able to
demonstrate that atorvastatin (40 mg/day) increased
serum PCSK9 levels by 34% compared to placebo at
12 weeks, while lowering LDL-C by 42% [48]. In con-
trast, placebo treatment in the same study had no signif-
icant effect on either LDL-C levels or serum PCSK9
levels [48].
The fact that atorvastatin significantly increased
PCSK9 levels provided evidence that statins increase the
activity/nuclear translocation of sterol regulatory ele-
ment-binding protein-2 (SREBP-2) to such an extent
that increased levels of PCSK9 protein were present in
the serum. We concluded this was particularly impor-
tant since the ability to detect any increase in secreted
PCSK9 protein could have been negated by the
increased hepatic LDLR that would act to bind PCSK9
and remove it from the circulation. Therefore, we
hypothesized that atorvastatin treatment must have
increased expression and secretion of PCSK9 protein to
such an extent that circulating PCSK9 levels exceeded
LDLR binding, resulting in increased circulating levels
of PCSK9 protein being detected in serum.
Our initial observation that statin treatment in
humans caused an increase in serum PCSK9 levels was
soon confirmed by other groups, further suggesting the
importance of statin-induced increases in serum PCSK9
levels [34,49,50]. As interesting as these observations
were, they were somewhat limited in that the baseline
and endpoint analysis of samples did not allow for the
detailed time course of statin-induced PCSK9 increases
to be described. It was thus not clear at the time how
quickly the effect of statins on PCSK9 levels occurred or
whether the effect was sustained over time. As a result,
we conducted an additional larger study examining the
detailed time course of the effect of 80 mg/day
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measured serum PCSK9 and lipid levels during a 2-
week lead-in baseline period and every 4 weeks there-
after for 16 weeks. We observed in this subsequent
study that atorvastatin (80 mg/day) caused a rapid 47%
increase in serum PCSK9 after 4 weeks of treatment
that was completely sustained throughout 16 weeks of
dosing [51]. Interestingly, we also observed that while
PCSK9 levels were highly correlated with LDL-C at
baseline, atorvastatin (80 mg) completely abolished this
correlation [51].
In this study, we also compared baseline PCSK9 levels
to atorvastatin-induced changes in LDL-C (from base-
line to endpoint) to determine if baseline PCSK9 levels
might predict whom would respond most robustly to
atorvastatin treatment. We hypothesized that subjects
who had the highest PCSK9 levels might also have the
largest atorvastatin-induced LDL-C lowering effect. Con-
sistent with this hypothesis, there was a modest relation-
ship between baseline PCSK9 levels and changes in
LDL-C, with relatively higher baseline PCSK9 levels
tending to be associated with numerically greater
decreases in LDL-C [51]. This correlation, however, did
not achieve statistical significance [51].
These data, in conjunction with those of Costet and
colleagues who recently showed that atorvastatin 10 mg/
day increased PCSK9 levels by only 14% in patients after
6 weeks of therapy [52], suggested a clear dose response
effect for atorvastatin on PCSK9 levels, with increasing
doses of atorvastatin causing larger and larger percen-
tage increases in circulating PCSK9 levels. Available data
regarding the effect of atorvastatin on human serum
PCSK9 levels in controlled clinical trials where endpoint
PCSK9 levels could be compared to baseline levels is
summarized in Table 1, which shows that increasing
doses of atorvastatin result in dose-dependent increases
in circulating PCSK9 protein. Consistent with this pat-
tern, Lakoski and co-workers recently demonstrated in a
large trial that at a low dose of simvastatin (10 mg/day),
there was no significant increase in median circulating
PCSK9 levels [53].
As Figure 2 demonstrates, these data suggest that the
explanation for why increasing doses of statins fail to
achieve proportional LDL-C lowering is that statins
increase PCSK9 protein levels in a dose-dependent
fashion, and that the increased PCSK9 levels largely
negate further statin-induced increases in hepatic LDLR
levels. For some time, it has been known that statins fol-
low a rule of 6% in that whatever LDL-C reduction is
achieved at a starting dose of a given statin is only
improved upon an additional approximate 6% with each
doubling of the dose. This important observation of
non-dose dependent response for commonly prescribed
statins has led to much speculation about why statins
should affect LDL-C levels in such a manner. Our own
data, combined with data that other laboratories have
generated, suggest that statin-induced increases in
PCSK9 protein levels account for the less than expected,
incremental LDL-C lowering observed when the starting
dose of a statin is subsequently increased.
Besides statins, another commonly prescribed LDL-C
lowering medication is ezetimibe, which acts by blocking
uptake of dietary cholesterol from the gut by binding
the cholesterol transport protein Niemann-Pick C1-Like
1 (NPC1L1) [40,54-56]. By decreasing the amount of
cholesterol supplied to the liver through intestinal
uptake, ezetimibe decreases hepatic cholesterol levels,
leading to increased hepatic LDLR expression, which
results in increased LDL uptake from the plasma and
thus decreased circulating LDL-C levels [40,54-56]. Eze-
timibe lowers LDL-C by approximately 15-20%, which is
a smaller decrease than that achievable with statins, but
its effect appears to be additive to that of statins
[40,54-56].
With regard to the effect of ezetimibe on PCSK9
levels, there have been fewer studies than for statins.
A recent reports by Davignon and colleagues indicated
that when added onto statin therapy, ezetimibe further
increased PCSK9 levels beyond the increases observed
with statins alone [57]. In this study, the researchers
observed that patients treated with statins alone had an
approximately 45% increase in circulating PCSK9 levels,
while those treated with a combination of statins and
ezetimibe exhibited an approximately 77% increase in
PCSK9 protein levels [57]. At the present time, the
mechanism by which ezetimibe causes a further increase
in PCSK9 levels compared to statin treatment alone is
unclear, but is likely associated with reduced intestinal
cholesterol absorption and thus reduced hepatic choles-
terol to feedback regulate SREBP2 [40]. As a result of
Table 1 Effect of increasing doses of atorvastatin on serum PCSK9 levels
Atorvastatin Dose (mg/day) Duration of treatment (weeks) Increase in serum PCSK9 levels (%) Author and study (reference)
10 6 14 Costet et al. [52]
40 12 34 Careskey et al. [48]
80 16 47 Welder et al. [51]
These results summarize the available data regarding the effect of atorvastatin on human serum PCSK9 levels in controlled clinical trials in which endpoint PCSK9
levels could be compared to baseline levels. Treatment with increasing doses of atorvastatin resulted in dose-dependent increases in the levels of circulating
PCSK9 protein.
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clearly be warranted. Of particular importance will be to
determine the effect of ezetimibe alone on serum
PCSK9 levels and how it is modulated with the addition
of increasing doses of statins.
Fibrates and their effects on PCSK9 levels
Fibrates represent a class of medications that activate the
transcription factor peroxisome proliferator-activated
receptor a (PPARa) [58,59]. Activation of this receptor by
fibrates alters the transcription of multiple target genes
which play a key role in lipid metabolism [58,59]. In parti-
cular fibrates have been shown to reduce plasma levels of
triglycerides by approximately 30%-50% and have been
demonstrated to increase levels of HDL-C by 5%-15%
[58,59]. The effects on LDL-C are less consistent. In some
cases, fibrates may reduce LDL-C by as much as 15%-20%
although the effect can be variable, depending on the
patient population being studied and the type of hyperlipi-
demia present [58,59].
Previous data showing that statins increase PCSK9 levels
caused many researchers including our own group to
wonder about the effects of fibrates on PCSK9 levels. To
address this question, we studied the effect of a commonly
prescribed fibrate, fenofibrate, on circulating PCSK9
protein levels in patients treated with either fenofibrate
(200 mg/day) or placebo for 12 weeks. We observed that
fenofibrate significantly increased circulating PCSK9 levels
by 25% compared to baseline, while placebo treatment had
no effect on PCSK9 levels [60]. Interestingly, fenofibrate-
induced increases in serum PCSK9 levels were highly cor-
related with fenofibrate-induced changes in LDL-C levels.
Similar to what was observed with statins, these results
suggested an explanation for why fibrates might not
achieve as much LDL-C lowering as might otherwise be
expected [60].
The mechanism by which fenofibrate increased PCSK9
levels in this study was unclear. Fenofibrate belongs to a
class of drugs called PPAR-a agonists, which affect lipid
levels by altering transcription of a number of different
genes involved in lipoprotein and fatty acid metabolism
[61]. As a PPAR-a agonist, fenofibrate reduces hepatic
triglyceride synthesis and increases the breakdown of
triglyceride rich lipoproteins, while also enhancing cho-
lesterol efflux from the liver [62]. It is possible that
these effects on cholesterol and lipoprotein metabolism
may work indirectly within the hepatocyte to decrease
intracellular cholesterol levels, thus leading to increased
PCSK9 expression and secretion via a mechanism simi-
lar to that of statins. In light of the multiple pleiotropic
effects of fenofibrate [63], however, it is also possible
that fenofibrate may exert a direct effect within hepato-
cytes to stimulate increased PCSK9 synthesis and secre-
tion independent of SREBP-2.
Making matters somewhat more complex, there have
been conflicting observations concerning the effect of
fibrates on hepatocyte PCSK9 synthesis and secretion.
Previously, Mayne and co-workers reported that fibrates
increased human serum PCSK9 levels by 17% [64]. In
this study, however, analysis of PCSK9 levels was per-
formed using an immunoprecipitation and western blot-
ting method, which is a semi-quantitative rather than a
quantitative technique. In addition, the absolute levels of
PCSK9 present in human serum as reported by this
method were significantly greater than what our labora-
tory as well as several others have reported. Also, the
g r o u po fp a t i e n t sa n a l y z e di nt h i ss t u d yw a sr e l a t i v e l y
small and consisted of a mixture of patients on gemfi-
brozil and fenofibrate.
In contrast to this report, Kourimate and co-workers
demonstrated that fibrate treatment resulted in reduced
PCSK9 mRNA levels in hepatocytes [65]. This group
also went on to measure levels of PCSK9 protein
expression in hepatocytes and concluded that PCSK9
protein expression in hepatocytes was also reduced.
Again, similar to the work by Mayne and co-workers,
PCSK9 protein levels were measured by western blot-
ting. Kourimate and co-workers concluded from these
data that addition of a fibrate to pre-existing statin ther-
apy would result in suppression of circulating PCSK9
levels and thus enhanced LDL-C lowering activity of the
statin. On the other hand, Lambert and colleagues used
an ELISA method to report that fenofibrate treatment
(200 mg per day for 6 weeks) decreased plasma PCSK9
levels by 8% and that this decrease correlated with the
fenofibrate-induced decreases in circulating triglycerides
[66]. Similar to the observations by Mayne and collea-
gues, the absolute plasma levels of PCSK9 as reported
(-)
Lysosomal
LDLR
Lysosomal
degradation
Atorvastatin SREBP-2 PCSK9
Figure 2 Effect of atorvastatin on hepatocyte LDLR and PCSK9.
Atorvastatin increases the activity/nuclear translocation of sterol
regulatory element-binding protein-2 (SREBP-2), which is a
transcription factor that activates both the LDLR and PCSK9 genes.
This results in increased expression and secretion of PCSK9 protein,
which binds the LDLR and targets it for lysosomal degradation. This
likely prevents atorvastatin from causing as much increased LDLR
protein from being present on the hepatocyte plasma membrane
as might otherwise be expected.
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laboratory and several other groups have reported. The
same researchers concluded that fenofibrate-induced
decreases in PCSK9 might account for the modest
LDL-C reduction observed with fenofibrate [66].
The conclusions reached by these two groups were
different from those that we reached with regard to the
effect of fibrates on circulating PCSK9 protein levels.
O n ep o s s i b i l i t yf o rt h i sd i f f e r e n c em a yh a v eb e e nt h e
use of different analytical techniques than those used by
our laboratory and other laboratories. This possibility
seems even more likely in light of a very recent, thor-
ough study exploring the effects of fenofibrate on
PCSK9 serum levels in patients with diabetes. In their
recent report using a robust and specific assay, Costet
and colleagues demonstrated that 6 weeks of treatment
with fenofibrate (160 mg/day) increased serum PCSK9
by 26% [52]. This increase in circulating PCSK9 levels
was very similar to the increase of 25% that we observed
after 12 weeks of treatment using our own assay.
Therefore, at the current time, it seems likely that
fibrates share with statins the common property of
increasing serum PCSK9 protein levels. Unlike the situa-
tion for statins though, in which the mechanism for the
increase in PCSK9 is likely mediated through SREBP-2,
it is much less understood how fibrates actually increase
circulating PCSK9 protein levels. Certainly additional
studies will be needed to better understand the biology
of fibrate-induced PCSK9 increases.
Future directions for LDL-lowering therapies
In light of the genetic studies in humans showing PCSK9
mutations that decrease PCSK9 levels result in decreased
serum LDL-C and cardiovascular risk and the findings
that the utility of both statins and fibrates may be limited
due to the fact that they increase serum PCSK9 levels,
there has been tremendous increased interest in develop-
ing a PCSK9 inhibitor. One approach that has been
tested is to use an antisense oligonucleotide (ASO) to tar-
get PCSK9 mRNA. Graham and colleagues demonstrated
that this approach reduced total cholesterol by 53% in
mice fed a high-fat diet, while also causing a 2-fold
increase in hepatic LDLR protein levels [14]. Similarly,
Gupta and co-workers reported that an ASO lowered
PCSK9 mRNA expression in mice by 60% and increased
hepatic LDLR protein expression by almost 3-fold [67].
Comparable results have also been reported using a
siRNA approach by Fitzgerald and colleagues, who
demonstrated 60% reductions in PCSK9 mRNA and total
cholesterol in mice [68]. This same group also demon-
s t r a t e dt h a ts u c ha na p p r o a c hw a sp o s s i b l ei nan o n -
human primate model as well by showing that a single
siRNA injection produced long-lasting reductions in both
serum PCSK9 and LDL-C levels [68].
Due to the nature of PCSK9 protein and the way in
which it functions by binding the LDLR, several groups
have also attempted to generate neutralizing, fully
humanized anti-PCSK9 monoclonal antibodies to block
the interaction of PCSK9 with the LDLR at the protein
level. Preliminary results so far have been encouraging.
Chan and colleagues developed a monoclonal antibody
that binds a PCSK9 epitope required for recognition by
the LDLR. When administered to cynomolgus monkeys,
one injection of this antibody decreased serum LDL-C
by approximately 80%, and a decrease in LDL-C was
observed over the course of 10 days [25]. In a separate,
recent report, Ni and co-workers developed a monoclo-
nal PCSK9 antibody that was neutralizing not only to
wild type PCSK9 but also to gain of function mutants
including D374Y [26]. When this antibody was adminis-
tered to rhesus monkeys, LDL-C was decreased from
20-50% over a 2-week long period, even though the
antibody had a relatively short half-life.
These observations clearly established a proof-of-
concept that a neutralizing anti-PCSK9 monoclonal
antibody is capable of reducing LDL-C levels in pri-
mates. One of the big remaining questions, however,
relates to the durability of such a therapeutic approach
in actual patients. In order to understand how feasible
such an approach will ultimately be in the clinic, it is
important to understand 2 key characteristics of PCSK9
- its half-life and what the absolute circulating levels are.
With regard to the first issue, the half-life of PCSK9
appears to be relatively short, presumably because
PCSK9 in the plasma is rapidly bound by LDLR and/or
similar type receptors. The best current estimates for
the circulating half-life are somewhere between 5 and
30 minutes [11,19].
With regard to the absolute levels of circulating
PCSK9 protein, there is currently less agreement. Part of
the problem has been the relative difficulty of develop-
ing robust methods to measure PCSK9 in human
serum. When analyzed by western blotting under redu-
cing, denaturing conditions, intact PCSK9 protein co-
migrates almost precisely with human albumin, which is
present in the serum at a concentration of approxi-
mately 4 g/dl. Because of this, it is extremely difficult to
accurately gauge human serum levels when performing
straight western blotting procedures alone. As Figure 3
demonstrates, when suitable immunoprecipitation is
performed, followed by western blotting, it becomes
easier to visualize the PCSK9 band, but also apparent
that there is at least one additional band which almost
precisely co-migrates with human IgG heavy chain
under reducing denaturing conditions. This second
band has been described as a furin cleavage product of
PCSK9 [49], and can be almost as intense as the intact
protein itself.
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sure PCSK9 protein, it is possible depending on the epi-
topes recognized by the capture and conjugate
antibodies to measure either total circulating PCSK9 or
just intact PCSK9. Furthermore, our laboratory has also
noticed that some antibodies may have altered affinity
for recombinant PCSK9 protein when it is expressed
with a His tag versus having no His tag [47,48,51,60]. In
addition, it has also been suggested that expressed
PCSK9 protein may self-associate to form multimers
[69], which might further complicate accurate measure-
ment of PCSK9 levels in serum. To investigate this pos-
sibility, we performed experiments pairing each of our
monoclonal antibodies with itself in a sandwich ELISA
format. In our experience, homomultimeric proteins are
able to be detected by such a configuration, but we were
not able to measure any signal when using the same
anti-PCSK9 monoclonal antibody as both a capture and
conjugate antibody in a sandwich ELISA (unpublished
data). These results suggested to us that PCSK9 may
not form multimers; however, this possibility cannot be
excluded. Undoubtedly, these aspects of the molecule
may account at least in part for some of the difference
in the absolute values of human serum PCSK9 reported
using various ELISA methods.
Despite these technical challenges, however, a consen-
sus appears to be forming that normal serum PCSK9
levels are somewhere around 100-1,000 ng/ml
[47-53,57]. If these estimates for half-life and circulating
levels are correct, then the liver must be constantly
secreting large amounts of PCSK9 protein into the cir-
culation. At one end of the spectrum, assuming a half-
life of 30 minutes, a circulating level of 100 ng/ml and a
plasma volume of 2.5 liters, the liver would be secreting
6 mg/day of PCSK9 protein into the plasma. At the
other end of the spectrum, assuming a half-life of 5
min, a circulating level of 1,000 ng/ml and a plasma
volume of 2.5 liters, the liver would be secreting 360
mg/day of PCSK9 protein into the plasma.
The true amount is probably somewhere between
these 2 extreme estimates, but going through this exer-
cise demonstrates that there is a significant amount of
circulating PCSK9 protein that would have to be neutra-
lized by a monoclonal antibody. As a result, it is far
from certain that an anti-PCSK9 monoclonal antibody
can be practically developed. The fact that it may
be possible, however, combined with the fact that an
anti-PCSK9 monoclonal antibody should theoretically be
synergistic or at least additive to statins with regard to
LDL-C lowering makes the development of such a
biotherapeutic a clear goal.
If this goal cannot be attained, however, the data
obtained so far showing that statins, fibrates and ezeti-
mibe all increase serum PCSK9 levels strongly suggest
that any novel LDL-C-lowering compound that acts to
decrease PCSK9 levels should be able to be combined
with the currently prescribed medications to result in
further LDL-C lowering than has ever been possible to
date. Furthermore, it may also be safe to speculate that
novel lipid-lowering medications that are PCSK9 neu-
tral (meaning that while they do not decrease, they
also do not increase PCSK9 levels) may be combined
with currently prescribed medications to enable greater
LDL-C lowering than can be achieved at the present
time.
Conclusions
Certainly, the past decade has seen an explosion in our
knowledge about PCSK9 and the role that it plays in the
regulation of LDL-C levels. In less than 10 years, we have
witnessed the discovery of the protein, the finding that
mutations in PCSK9 can drastically affect LDL-C levels,
an understanding of the mechanism by which PCSK9
250-
148-
98-
64-
50
PCSK9
Possible furin 
50-
36-
22-
cleavage product
22-
16- PCSK9
propeptide pp p
Figure 3 Characterization of PCSK9 protein in human serum.
When immunoprecipitated from human serum and analyzed in our
laboratory by subsequent western blotting under reducing and
denaturing conditions, PCSK9 migrates as an intact band (top
arrow) that co-migrates with recombinant PCSK9 protein (rPCSK9)
[51,60]. In addition, a band of approximately 55 kD is also present
(middle arrow), and this band had been described as representing a
furin cleavage product of the intact protein [49]. The band at the
very bottom of the blot represents the propeptide which remains
tightly but non-covalently associated during the
immunoprecipitation step, but is subsequently separated by
denaturation prior to western blotting (lower arrow).
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measure its circulating levels. These advances have
allowed multiple researchers to measure PCSK9 protein
levels in human serum and demonstrate that commonly
prescribed lipid lowering medications (including statins,
fibrates, and ezetimibe) increase circulating PCSK9 levels.
Preliminary proof-of-concept studies showing that neu-
tralizing anti-PCSK9 antibodies can significantly lower
LDL-C have also occurred, suggesting that addition of
PCSK9 inhibitors to current therapies may allow for low-
ering LDL-C to a greater extent than has previously been
achievable. While it is impossible to predict accurately
what the next decade will hold, if the past one is any indi-
cation, it is safe to bet that the development of novel
LDL-C-lowering compounds that decrease or inhibit
PCSK9 or that act through PCSK9-independent pathways
will be a top priority of multiple research laboratories
around the world.
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